These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28639703)

  • 1. An assessment of differences in costs and health benefits of serology and NAT screening of donations for blood transfusion in different Western countries.
    Janssen MP; van Hulst M; Custer B;
    Vox Sang; 2017 Aug; 112(6):518-525. PubMed ID: 28639703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a web-based application and multicountry analysis framework for assessing interdicted infections and cost-utility of screening donated blood for HIV, HCV and HBV.
    Custer B; Janssen MP; Hubben G; Vermeulen M; van Hulst M
    Vox Sang; 2017 Aug; 112(6):526-534. PubMed ID: 28597489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of adding nucleic acid testing to hepatitis B, hepatitis C, and human immunodeficiency virus screening of blood donations in Zimbabwe.
    Mafirakureva N; Mapako T; Khoza S; Emmanuel JC; Marowa L; Mvere D; Postma MJ; van Hulst M
    Transfusion; 2016 Dec; 56(12):3101-3111. PubMed ID: 27696441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States.
    Marshall DA; Kleinman SH; Wong JB; AuBuchon JP; Grima DT; Kulin NA; Weinstein MC
    Vox Sang; 2004 Jan; 86(1):28-40. PubMed ID: 14984557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health and economic impact of posttransfusion hepatitis B and cost-effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union.
    Pereira A
    Transfusion; 2003 Feb; 43(2):192-201. PubMed ID: 12559015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of additional blood screening tests in the Netherlands.
    Borkent-Raven BA; Janssen MP; van der Poel CL; Bonsel GJ; van Hout BA
    Transfusion; 2012 Mar; 52(3):478-88. PubMed ID: 21880046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
    Busch MP
    Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancing blood transfusion safety using molecular detection in the country of Georgia.
    Alkhazashvili M; Bloch EM; Shadaker S; Kuchuloria T; Getia V; Turdziladze A; Armstrong PA; Gamkrelidze A
    Transfus Clin Biol; 2023 Aug; 30(3):307-313. PubMed ID: 36907246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of additional hepatitis B virus nucleic acid testing of individual donations or minipools of six donations in the Netherlands.
    Borkent-Raven BA; Janssen MP; van der Poel CL; de Wit GA; Bonsel GJ; van Hout BA
    Transfusion; 2009 Feb; 49(2):311-9. PubMed ID: 19389213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening the Blood Supply for Zika Virus in the 50 U.S. States and Puerto Rico: A Cost-Effectiveness Analysis.
    Russell WA; Stramer SL; Busch MP; Custer B
    Ann Intern Med; 2019 Feb; 170(3):164-174. PubMed ID: 30615781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing infection transmission in solid organ transplantation through donor nucleic acid testing: a cost-effectiveness analysis.
    Lai JC; Kahn JG; Tavakol M; Peters MG; Roberts JP
    Am J Transplant; 2013 Oct; 13(10):2611-8. PubMed ID: 24034208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of HCV and HIV-1 antibody negative infections in Scottish and Northern Ireland blood donations by nucleic acid amplification testing.
    Jarvis LM; Dow BC; Cleland A; Davidson F; Lycett C; Morris K; Webb B; Jordan A; Petrik J
    Vox Sang; 2005 Oct; 89(3):128-34. PubMed ID: 16146504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands.
    van Hulst M; Hubben GA; Sagoe KW; Promwong C; Permpikul P; Fongsatitkul L; Glynn DM; Sibinga CT; Postma MJ
    Transfusion; 2009 Dec; 49(12):2729-42. PubMed ID: 19709093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden.
    Davidson T; Ekermo B; Gaines H; Lesko B; Åkerlind B
    Transfusion; 2011 Feb; 51(2):421-9. PubMed ID: 20849409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of HIV screening of blood donations in Accra (Ghana).
    van Hulst M; Sagoe KW; Vermande JE; van der Schaaf IP; van der Tuuk Adriani WP; Torpey K; Ansah J; Mingle JA; Smit Sibinga CT; Postma MJ
    Value Health; 2008; 11(5):809-19. PubMed ID: 18489518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.
    Vermeulen M; Lelie N; Sykes W; Crookes R; Swanevelder J; Gaggia L; Le Roux M; Kuun E; Gulube S; Reddy R
    Transfusion; 2009 Jun; 49(6):1115-25. PubMed ID: 19309474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: impact of individual-donation nucleic acid testing, 2004 through 2009.
    Al Shaer L; AbdulRahman M; John TJ; AlHashimi A
    Transfusion; 2012 Nov; 52(11):2300-9. PubMed ID: 22691239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
    Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR;
    Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus.
    Li L; Chen PJ; Chen MH; Chak KF; Lin KS; Tsai SJ
    Transfusion; 2008 Jun; 48(6):1198-206. PubMed ID: 18422856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
    Hourfar MK; Jork C; Schottstedt V; Weber-Schehl M; Brixner V; Busch MP; Geusendam G; Gubbe K; Mahnhardt C; Mayr-Wohlfart U; Pichl L; Roth WK; Schmidt M; Seifried E; Wright DJ;
    Transfusion; 2008 Aug; 48(8):1558-66. PubMed ID: 18466173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.